Krai Chatamra

2.0k total citations · 1 hit paper
31 papers, 1.4k citations indexed

About

Krai Chatamra is a scholar working on Neurology, Epidemiology and Psychiatry and Mental health. According to data from OpenAlex, Krai Chatamra has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Neurology, 12 papers in Epidemiology and 10 papers in Psychiatry and Mental health. Recurrent topics in Krai Chatamra's work include Parkinson's Disease Mechanisms and Treatments (20 papers), Neurological disorders and treatments (17 papers) and Restless Legs Syndrome Research (12 papers). Krai Chatamra is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (20 papers), Neurological disorders and treatments (17 papers) and Restless Legs Syndrome Research (12 papers). Krai Chatamra collaborates with scholars based in United States, Germany and Sweden. Krai Chatamra's co-authors include Janet Benesh, Per Odin, David G. Standaert, Hubert H. Fernandez, Weining Robieson, Alberto J. Espay, Ahmed A. Othman, Arvydas Vanagunas, Angelo Antonini and Coleen Hall and has published in prestigious journals such as Neurology, The Lancet Neurology and The British Journal of Psychiatry.

In The Last Decade

Krai Chatamra

30 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

2013 487 citations C. Warren Olanow, Karl Kieburtz et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Krai Chatamra United States	14	1.1k	345	230	142	125	31	1.4k
Jordan Dubow United States	14	433 0.4×	179 0.5×	90 0.4×	104 0.7×	121 1.0×	55	845
Martijn Broen Netherlands	11	649 0.6×	132 0.4×	112 0.5×	91 0.6×	116 0.9×	17	825
Sotirios A. Parashos United States	22	848 0.7×	135 0.4×	315 1.4×	313 2.2×	131 1.0×	42	1.3k
Y. Naidu United Kingdom	6	643 0.6×	190 0.6×	91 0.4×	64 0.5×	118 0.9×	11	717
Margarita Pondal Spain	16	466 0.4×	317 0.9×	66 0.3×	346 2.4×	106 0.8×	20	1.1k
V. Campos Arillo Spain	11	481 0.4×	124 0.4×	45 0.2×	154 1.1×	84 0.7×	15	680
J R Playfer United Kingdom	12	308 0.3×	95 0.3×	69 0.3×	156 1.1×	110 0.9×	21	690
Daniela Calandrella Italy	16	672 0.6×	144 0.4×	173 0.8×	134 0.9×	46 0.4×	36	830
Michelle Fullard United States	14	517 0.4×	90 0.3×	105 0.5×	106 0.7×	110 0.9×	30	864
Henry Moore United States	13	454 0.4×	66 0.2×	60 0.3×	114 0.8×	105 0.8×	33	659

Countries citing papers authored by Krai Chatamra

Since Specialization

Citations

This map shows the geographic impact of Krai Chatamra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krai Chatamra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krai Chatamra more than expected).

Fields of papers citing papers by Krai Chatamra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krai Chatamra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krai Chatamra. The network helps show where Krai Chatamra may publish in the future.

Co-authorship network of co-authors of Krai Chatamra

This figure shows the co-authorship network connecting the top 25 collaborators of Krai Chatamra. A scholar is included among the top collaborators of Krai Chatamra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krai Chatamra. Krai Chatamra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernandez, Hubert H., James T. Boyd, Victor S.C. Fung, et al.. (2018). Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders. 33(6). 928–936. 69 indexed citations

Othman, Mohamed I. A., Matthew Rosebraugh, Krai Chatamra, Charles Locke, & Sandeep Dutta. (2017). Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. Journal of Parkinson s Disease. 7(2). 275–278. 32 indexed citations

Conradt, Christian, et al.. (2017). Increased Prevalence of Polyneuropathy in Parkinson’s Disease Patients: An Observational Study. Journal of Parkinson s Disease. 8(1). 141–144. 6 indexed citations

Murata, Miho, Masahito Mihara, Kazuko Hasegawa, et al.. (2016). Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. npj Parkinson s Disease. 2(1). 16020–16020. 13 indexed citations

Epstein, Michael, David A. Johnson, Robert H. Hawes, et al.. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clinical and Translational Gastroenterology. 7(3). e159–e159. 36 indexed citations

Fernandez, Hubert H., Weining Robieson, Krai Chatamra, et al.. (2016). Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease. npj Parkinson s Disease. 2(1). 16015–16015. 8 indexed citations

Dubow, Jordan, Krai Chatamra, Susan Eaton, Coleen Hall, & Janet Benesh. (2015). Interim Results of a Phase 3b Study Assessing the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel On Non-Motor Symptoms in Subjects with Advanced Parkinson’s Disease (P6.041). Neurology. 84(14_supplement).

Slevin, John T., Hubert H. Fernandez, Cindy Zadikoff, et al.. (2015). Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients. Journal of Parkinson s Disease. 5(1). 165–174. 85 indexed citations

Lew, Mark, John T. Slevin, Rejko Krüger, et al.. (2015). Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism & Related Disorders. 21(7). 742–748. 15 indexed citations

10.

Othman, Ahmed A., Krai Chatamra, Mohamed‐Eslam F. Mohamed, et al.. (2015). Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety. Clinical Pharmacokinetics. 54(9). 975–984. 16 indexed citations

11.

Epstein, Michael, David H. Johnson, Robert H. Hawes, et al.. (2014). Gastrointestinal Safety of the Levodopa-Carbidopa Intestinal Gel Delivery System in Treating Advanced Parkinson’s Patients (P7.085). Neurology. 82(10_supplement). 2 indexed citations

12.

Antonini, Angelo, Victor S.C. Fung, James T. Boyd, et al.. (2014). Changes In Troublesome Dyskinesia And Its Relationship With Dose In Advanced Parkinson’s Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel Infusion (P7.071). Neurology. 82(10_supplement). 1 indexed citations

13.

Fernandez, Hubert H., David G. Standaert, Robert A. Hauser, et al.. (2014). Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results. Movement Disorders. 30(4). 500–509. 187 indexed citations

14.

Fernandez, Hubert H., Arvydas Vanagunas, Per Odin, et al.. (2013). Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism & Related Disorders. 19(3). 339–345. 73 indexed citations

15.

Olanow, C. Warren, Karl Kieburtz, Per Odin, et al.. (2013). Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. The Lancet Neurology. 13(2). 141–149. 487 indexed citations breakdown →

16.

Nyholm, Dag, Per Odin, Anders Johansson, et al.. (2012). Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal. 15(2). 316–323. 94 indexed citations

17.

Ryvlin, Philippe, Reetta Kälviäinen, Florian von Raison, et al.. (2010). Pregabalin in partial seizures: a pragmatic 21‐week, open‐label study (PREPS). European Journal of Neurology. 17(5). 726–732. 9 indexed citations

18.

Arnold, Lesley M., Krai Chatamra, Ian Hirsch, & Malcolm Stoker. (2010). Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics. 32(9). 1618–1632. 24 indexed citations

19.

Montgomery, Stuart, Krai Chatamra, L. Pauer, Ed Whalen, & F. Baldinetti. (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. The British Journal of Psychiatry. 193(5). 389–394. 90 indexed citations

20.

Carrasco, Melisa, et al.. (2007). Preliminary results evaluating cognitive function in elderly from double-blind, placebo-controlled trial of pregabalin in generalized anxiety disorder (gad). European Psychiatry. 22. S279–S280. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact